Add office photos
Engaged Employer
Dr. Reddy's
4.0
based on 7.4k Reviews
Video summary
Proud winner of ABECA 2025 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Dr. Reddy's
Company Summary
We are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’
Overall Rating
4.0/5
based on 7.4k reviews
3% above
industry average
Highly rated for
Salary, Skill development, Company culture
Critically rated for
Promotions
Work Policy
Work from office
74% employees reported
Monday to Friday
40% employees reported
Flexible timing
67% employees reported
No travel
38% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
491 employees reported
Health insurance
411 employees reported
Cafeteria
279 employees reported
Child care facility
262 employees reported
View all benefits
About Dr. Reddy's
Founded in1984 (41 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
Websitedrreddys.com
Primary Industry
Other Industries
View in video summary
We started in 1984 with a modest investment and a bold vision. Today, with research and development centres, manufacturing facilities and commercial presence across the globe, we serve over half a billion patients worldwide. We aspire to triple our reach and touch over 1.5 billion patients by 2030.
We are committed to providing access to affordable and innovative medicines, driven by our purpose of ‘Good Health Can’t Wait’.
Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically-differentiated assets and digital healthcare.
Report error
ABECA - AmbitionBox Employee Choice Awards
Best of the best, rated by employees
Dr. Reddy's won India’s Largest Employee Choice Awards in Large Companies Category.
Top Rated Pharma Company
Share
Dr. Reddy's Ratings
based on 7.4k reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
3.9k
4
2k
3
766
2
311
1
455
Category Ratings
3.9
Salary
3.9
Skill development
3.8
Company culture
3.8
Work-life balance
3.7
Work satisfaction
3.5
Job security
3.3
Promotions
Dr. Reddy's is rated 4.0 out of 5 stars on AmbitionBox, based on 7.4k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Dr. Reddy's
based on 7.1k reviews
3.9
Rated by 856 Women
Rated 3.8 for Work-life balance and 3.8 for Company culture
4.0
Rated by 6.2k Men
Rated 4.0 for Skill development and 3.9 for Company culture
Work Policy at Dr. Reddy's
based on 781 reviews in last 6 months
Work from office
74%
Hybrid
22%
Permanent work from home
4%
Dr. Reddy's Reviews
Top mentions in Dr. Reddy's Reviews
+ 5 more
Compare Dr. Reddy's with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 7.4k reviews | 4.1/5 based on 6.7k reviews | 4.1/5 based on 6.8k reviews | 4.1/5 based on 7.6k reviews |
Highly Rated for | Skill development Salary Work-life balance | Skill development Company culture Work-life balance | Salary Skill development Job security | Skill development Salary Work-life balance |
Critically Rated for | Promotions |  No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 74% employees reported | Work from office 82% employees reported | Work from office 67% employees reported | Work from office 72% employees reported |
Rating by Women Employees | 3.9 Good rated by 856 women | 4.1 Good rated by 416 women | 4.0 Good rated by 516 women | 4.0 Good rated by 778 women |
Rating by Men Employees | 4.0 Good rated by 6.2k men | 4.1 Good rated by 6k men | 4.1 Good rated by 6k men | 4.1 Good rated by 6.5k men |
Job security | 3.5 Good | 3.7 Good | 3.9 Good | 3.7 Good |
View more
Dr. Reddy's Salaries
Dr. Reddy's salaries have received with an average score of 3.9 out of 5 by 7.4k employees.
Team Member
(4.1k salaries)
Unlock
₹3.5 L/yr - ₹10.3 L/yr
Analytical Scientist
(894 salaries)
Unlock
₹5.8 L/yr - ₹12.8 L/yr
Team Lead
(534 salaries)
Unlock
₹11.7 L/yr - ₹21.2 L/yr
Area Sales Manager
(448 salaries)
Unlock
₹6.2 L/yr - ₹13 L/yr
Senior Team Member
(405 salaries)
Unlock
₹5.7 L/yr - ₹12 L/yr
Territory Manager
(350 salaries)
Unlock
₹3.5 L/yr - ₹7.4 L/yr
Scientist
(321 salaries)
Unlock
₹5.6 L/yr - ₹14.1 L/yr
Production Specialist
(312 salaries)
Unlock
₹3.5 L/yr - ₹7.8 L/yr
Research Associate
(287 salaries)
Unlock
₹4.5 L/yr - ₹10 L/yr
Medical Representative
(276 salaries)
Unlock
₹3.2 L/yr - ₹7 L/yr
Dr. Reddy's Interview Questions
Dr. Reddy's Jobs
Popular Designations Dr. Reddy's Hires for
Popular Skills Dr. Reddy's Hires for
Current Openings
Dr. Reddy's News
View all
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India
- Shares of companies like Infosys, Wipro, and HDFC Bank, among others, dropped after the US imposed a 50% tariff on India.
- Wipro ADR fell by 0.56% to $2.665, Infosys ADR was down by 0.43% to $16.13, and HDFC Bank ADR dropped by 0.03% to $75.71 on the American stock exchange.
- Dr. Reddy's Laboratories ADR experienced the largest decrease, plunging 1.65% to $13.445 on the NYSE.
- The situation is evolving, and updates are expected as the story progresses.
Bloomberg Quint | 6 Aug, 2025
Markets hold steady amid RBI’s repo rate decision, trade tension concerns persist
- The RBI's Monetary Policy Committee decided to keep the repo rate steady at 5.5% and maintained a neutral policy stance, with Governor Sanjay Malhotra highlighting concerns about uneven economic expansion and potential retail inflation risks.
- Asian Paints and HDFC Life led the Nifty gainers, while Wipro and Dr Reddy's Laboratories were among the decliners.
- RBI revised its consumer price index (CPI) forecast for FY26 to 3.7% from 4%, following a drop in retail inflation to 2.1% in June.
- Market breadth remained negative, with broader market indices underperforming benchmark indices, as concerns over global trade uncertainties loom.
HinduBusinessLine | 6 Aug, 2025
Sensex down 300 pts, pharma index down 3%, Sun Pharma, Dr Reddy’s Lab, Cipla among top losers
- Sensex and Nifty declined with Sensex down by 334.49 points (0.41%) and Nifty 50 by 125.50 points (0.51%) as of 12.41 pm.
- Midcap and smallcap indexes decreased by 0.62% and 0.74% respectively with a continuation of the trend likely for smallcaps due to high valuations.
- Pharma, healthcare, IT, oil & gas, and metal stocks faced losses. Sun Pharma, Dr Reddy’s Lab, and Cipla were among the top losers.
- Gainers on Nifty 50 included Eicher Motors, Trent, and Asian Paints, while stocks like Sun Pharma, Dr. Reddy’s Lab, and Cipla were major laggards.
HinduBusinessLine | 1 Aug, 2025
Markets extend losses at mid-session as pharma stocks lead decline amid Trump tariff concerns
- Pharmaceutical stocks, including Sun Pharma, Dr Reddy's Laboratories, and Cipla, faced significant losses amid concerns over potential US trade restrictions.
- Steel and energy stocks were also under pressure, with Tata Steel and ONGC declining due to investor worries over trade tensions.
- Despite the market decline, select consumer and auto stocks like Trent, Eicher Motors, and Asian Paints saw gains, offering some relief.
- The market breadth remained weak, with Nifty Next 50 and Nifty Midcap 100 falling, while the financial services sector showed relative resilience.
HinduBusinessLine | 1 Aug, 2025
Trump Tariff Impact: Textiles, Pharma, Oil & Gas, Electronic Equipment Face Threat
- US President Trump's 25% tariff on Indian exports can impact key industries like pharmaceuticals, textiles, auto components, chemicals, and energy.
- Auto and auto ancillary companies, including Sona BLW, Ramkrishna Forgings, Bharat Forge, and Tata Motors, with high exposure to the US face significant revenue risk.
- Pharmaceutical companies like Gland Pharma, Aurobindo Pharma, Dr. Reddy's, and others may experience significant earnings risk due to potential tariffs on Indian generics by the US.
- Textiles and garments, energy sector, solar, chemical companies, seafood exporters, and consumer goods companies are also vulnerable to the impact of the tariffs.
Bloomberg Quint | 31 Jul, 2025
Seven pharma stocks that will be in the spotlight in today’s trade (July 28)
- Sun Pharma, Lupin, and Dr. Reddy’s Laboratories are facing drug recalls in the US market due to manufacturing issues and product mix-up.
- Sun Pharma is recalling 5,448 bottles of a generic medication in the US due to "Failed Dissolution Specifications".
- Dr. Reddy’s Laboratories has invested Rs 565.40 crore in its subsidiary, DRL Russia, acquiring a total equity stake of 45.19%.
- Alembic Pharmaceuticals has received FDA approval for its Carbamazepine Extended-Release Tablets USP, used as an anticonvulsant and for pain treatment.
HinduBusinessLine | 28 Jul, 2025
India-UK FTA sparks rally in leather, textile, pharma stocks
- India and UK sign a trade agreement to boost trade and aim to double the current trade of USD 56 billion by 2030.
- The FTA leads to a rally in stocks of leather, textile, and pharma companies in India.
- Stocks of companies like Mirza International, Trident, Dr Reddy’s Laboratories, and others surged after the trade agreement.
- The FTA is seen positively by the market, projecting India as a nation committed to free trade and potentially improving chances of a fair-trade deal with the US.
HinduBusinessLine | 25 Jul, 2025
Nifty prediction today – July 24, 2025: Index might stay sideways
- The advance/decline ratio indicates a bearish bias with Eternal and Dr Reddy’s Laboratories as top gainers while Trent and Shriram Finance are the top losers.
- Nifty Healthcare index is the top gainer among sectors, while Nifty IT is the top loser.
- Nifty futures opened higher today but are now trading around 25,200, down nearly 0.2 per cent.
- Nifty futures might oscillate within 25,080 and 25,300; a breakout above 25,300 could lead to an upswing towards 25,650, while a decline below 25,080 could extend the fall to 25,000.
HinduBusinessLine | 24 Jul, 2025
Dr. Reddy's Q1 Review: Brokerage Split On Margin Recovery — What's The Takeaway?
- Dr. Reddy's Laboratories reported modest Q1 results with a 1.8% YoY rise in net profit, missing analyst expectations.
- Revenue grew by 11.4% to Rs 8,572 crore, but the bottom line of Rs 1,418 crore fell short of Bloomberg’s consensus estimate.
- Brokerages had mixed reviews on the stock, with some pointing out long-term growth drivers like the pending approval of semaglutide (Sema) and cost optimization.
- While Morgan Stanley maintained an 'Equal-weight' rating, Bank of America reiterated a 'Buy' rating and Macquarie took a more cautious view with a 'Neutral' rating.
Bloomberg Quint | 24 Jul, 2025
Q1 Scorecard: Firms Comprising 50% Of Nifty Weightage Post Earnings — A Mix Of Beats, Meets & Misses
- As the Q1 earnings season progresses, 16 out of the Nifty 50 companies, representing over 50% of the index’s weightage, have reported their results so far. The early trend shows a mixed picture with three companies beating Street estimates, five missing expectations, and eight meeting projections.
- In the IT sector, most large-cap players have seen a decrease in constant currency (CC) growth, except Infosys which delivered the highest CC growth among peers. Deal wins were positive overall, with companies like TCS and Infosys showing significant wins. Margins have held up despite revenue challenges due to global uncertainties.
- Eternal Ltd. (formerly Zomato) and ICICI Bank were among the notable outperformers this quarter, while Axis Bank and Reliance Industries faced challenges. JSW Steel surprised positively on margins. Dr. Reddy’s Laboratories saw US market headwinds, and Tata Consumer Products reported margin contractions.
- Some key companies like HDFC Bank, Infosys, Tata Consultancy Services, and UltraTech Cement met earnings estimates. Jio Financial Services, Tech Mahindra, HDFC Life Insurance, and Wipro also delivered results in line with expectations, showcasing steady operational performance and business progress.
NDTV Profit | 23 Jul, 2025
Powered by
Dr. Reddy's Subsidiaries
Aurigene Oncology Limited
4.2
• 276 reviews
Aurigene Pharmaceutical Services
4.2
• 265 reviews
SVAAS Wellness
3.7
• 16 reviews
Report error
Dr. Reddy's Offices
Compare Dr. Reddy's with
Cipla
4.1
Sun Pharmaceutical Industries
4.1
Lupin
4.1
Zydus Lifesciences
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.8
Macleods Pharmaceuticals
3.6
Viatris
4.2
Alembic Pharmaceuticals
4.0
Abbott
4.1
Glenmark Pharmaceuticals
3.8
Ipca Laboratories
3.9
Alkem Laboratories
3.9
Mankind Pharma
3.8
Torrent Pharmaceuticals
3.9
MSN Laboratories
3.6
Ajanta Pharma
3.9
Akums Drugs & Pharmaceuticals Limited
4.3
GlaxoSmithKline Pharmaceuticals
4.1
Contribute & help others!
You can choose to be anonymous
Companies Similar to Dr. Reddy's
Cipla
Manufacturing, Pharma
4.1
• 7.6k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.1
• 6.8k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.7k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.0
• 6.6k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5.3k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.9k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.8
• 3.8k reviews
Macleods Pharmaceuticals
Biotech & Life sciences, Pharma
3.6
• 3.7k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.5k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.4k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.3k reviews
Glenmark Pharmaceuticals
Pharma
3.8
• 3.2k reviews
Dr. Reddy's FAQs
When was Dr. Reddy's founded?
Dr. Reddy's was founded in 1984. The company has been operating for 41 years primarily in the Pharma sector.
Where is the Dr. Reddy's headquarters located?
Dr. Reddy's is headquartered in Hyderabad / Secunderabad, Telangana. It operates in 6 cities such as Hyderabad / Secunderabad, Visakhapatnam, Baddi, Srikakulam, Bangalore / Bengaluru. To explore all the office locations, visit Dr. Reddy's locations.
How many employees does Dr. Reddy's have in India?
Dr. Reddy's currently has more than 21,000+ employees in India. Research & Development department appears to have the highest employee count in Dr. Reddy's based on the number of reviews submitted on AmbitionBox.
Does Dr. Reddy's have good work-life balance?
Dr. Reddy's has a Work-Life Balance Rating of 3.8 out of 5 based on 7,400+ employee reviews on AmbitionBox. 79% employees rated Dr. Reddy's 4 or above, while 21% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Dr. Reddy's work-life balance reviews for more details.
Is Dr. Reddy's good for career growth?
Career growth at Dr. Reddy's is rated as moderate, with a promotions and appraisal rating of 3.3. 21% employees rated Dr. Reddy's 3 or below, while 79% employees rated it 4 or above on promotions / appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Dr. Reddy's promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Dr. Reddy's?
Working at Dr. Reddy's comes with several advantages and disadvantages. It is highly rated for salary & benefits, skill development and company culture. However, it is poorly rated for promotions / appraisal, job security and work satisfaction, based on 7,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
85 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
